Mankind Pharma Limited's Acquisition of BSV: Integration Strategy for Value Realization

Sanjay Dhamija, Shikha Bhatia, Reena Nayyar

Product #:W47996

Supplier:Ivey

Discipline:Finance, Strategy

Setting:India, 2024

Details:Case (PDF) • 14 pages • 2026-04-06

Your Price:

$9.71

Purchase this material with a free Educator Account and enjoy more benefits:

Free Educator Copy
Free Teaching Notes
Build your coursepack
Discounted academic price

Mankind Pharma Limited (MPL) strategically acquired BSV Group (BSV), a niche value-focused, superspecialized biopharmaceutical company. MPL, traditionally a high-volume generics player, saw the deal as an opportunity to climb the value chain and diversify into premium therapeutic areas. The acquisition offered clear strategic synergies for MPL, but the deal came at a steep price, raising concerns about whether MPL had overpaid. Post-acquisition, MPL’s leadership faced a critical decision: How could they integrate BSV in a way that would unlock its full strategic potential and justify the premium paid?

Learning Objectives

This case is best suited for senior undergraduate- and graduate-level business school students in courses focusing on M&A, corporate restructuring, competitive strategy, strategic management, and investment banking. Students will need to understand the process of valuation using multiples to be fully able to work on this case. After working through the case and assignment questions, students will be able to do the following:

Examine the reasons for a shift in strategy from organic to inorganic growth.
Identify possible synergies that drive mergers and acquisitions (M&A).
Assess the fair value of a target company.
Evaluate the risks associated with debt financing of an acquisition.
Recommend the post-acquisition integration approach most suitable for an acquirer.

Mankind Pharma Limited's Acquisition of BSV: Integration Strategy for Value Realization

Subjects:

Industries:

Geography:

Learning Objectives